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Received December 22, 2011; accepted July 10, 2012AbstractBackground: Deep vein thrombosis (DVT) is a potentially progressive disease with complex clinical sequelae. The clinical practice guidelines of
the American College of Chest Physicians (ACCP) recommend various treatments for all patients with objectively proven DVT. This study
retrospectively compares enoxaparin with CDT on treatment efficacy and safety and the evolution of acute proximal DVT in the lower limbs.
Methods: This study comprised 53 patients with acute proximal DVT, who received either CDT followed by intravenous unfractionated heparin
(UFH) or adjusted subcutaneous low-molecular-weight heparin (LMWH) (enoxaparin) for 7e14 days. Warfarin was administered to all patients
for at least 6 months. The study endpoints included the evolution of DVT and treatment efficacy and safety, which were assessed with frequent
duplex ultrasounds, plethysmography, and venography. The mean duration of the follow-up was 15.2 months.
Results: In the CDT group, patency of the iliofemoral vein segment was observed in 42.3% of the patients after 1 week ( p < 0.001) and in 69.2%
after 6 months. In the control group, patency was present in 15.4% of the patients after 3 months and in 38.5% after 6 months ( p ¼ 0.05).
Femoral venous obstruction was found in 30.8% of CDT patients and in 61.5% of the control group ( p ¼ 0.05). Furthermore, femoral venous
insufficiency was present in 46.2% of the CDT group and 53.9% of the control group after 6 months ( p ¼ 0.587). After 12 months, post-
thrombotic syndrome (PTS) was found in 19.2% of the CDT patients compared to 50% of the LMWH group ( p ¼ 0.04).
Conclusion: Duplex ultrasound analysis of thrombus progression is useful for assessing the treatment of a patient with acute proximal DVT. In
this study, patients undergoing CDT experienced higher thrombus resolution and early recanalization of their veins, which may preserve venous
function and further prevent development of post-thrombotic syndrome.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Deep vein thrombosis (DVT) is a potentially progressive
disease with complex clinical sequelae, such as pulmonary
embolism (PE) and post-thrombotic syndrome (PTS). Although
the clinical practice guidelines of theAmericanCollege ofChest
Physicians (ACCP) recommend treatment with anticoagulation
[i.e., either adjusted subcutaneous low-molecular-weight* Corresponding author. Dr. Tao-Cheng Wu, Division of Cardiology,
Department of Medicine, Taipei Veterans General Hospital, 201, Section 2,
Shih-Pai Road, Taipei 112, Taiwan, ROC.
E-mail address: davidlee0501@hotmail.com.tw (T.-C. Wu).
1726-4901/$ - see front matter Copyright  2013 Elsevier Taiwan LLC and the C
http://dx.doi.org/10.1016/j.jcma.2013.01.006heparin (LMWH) or intravenous unfractionated heparin (UFH)
followed by oral anticoagulation] for all patients with objec-
tively proven DVT, LMWH is as clinically effective as UFH and
presents fewer hemorrhagic complications.1e4 However, this
therapy does not directly promote thrombus dissolution to
reduce the thrombus burden, nor does it preserve venous valve
function and protect against PTS manifestations, which can
appear several months to years after the acute episode of DVT.
Recent studies have found that 49e60%of patients develop PTS
within 2 years after initial treatment of proximal DVT.5,6
Recently, catheter-directed intrathrombus thrombolysis
(CDT) has been recommended as a new therapy for DVThinese Medical Association. All rights reserved.
Table 1
Demographic and clinical characteristics of the study patients.
Characteristic Anticoagulation
group (n ¼ 26)
CDT group
(n ¼ 27)
p
Age, mean  SD years 59.8  19.5 62.4  16.7 0.682
Female gender, n (%) 12 (46.2%) 14 (51.9%) 0.786
Left lower leg DVT 16 (61.5%) 14 (51.9%) 0.583
Duration of symptoms (days) 7.1  2.3 6.9  2.6 0.806
Clot locations (No)
Iliofemoral 14 (53.8%) 18 (66.7%) 0.406
Femoropopliteal 12 (46.2%) 9 (29.6%) 0.406
Predisposing factors
Malignancy 6 (23.1%) 4 (14,8%) 0.501
Smoking 7 (26.9%) 8 (29.6%) 1.000
Immobilization 5 (19.2 %) 5 (18.5 %) 1.000
Thrombophilia 3 (11.5%) 4 (14,8%) 1.000
Orthopedics surgery 7 (26.9%) 6 (22.2%) 0.757
Recent trauma 3 (11.5%) 3 (11.1%) 1.000
Hormonal replacement therapy 2 (7.7%) 3 (11.1%) 1.000
Oral contraceptive pill 4 (15.4%) 3 (11.1%) 0.704
DVT ¼ deep vein thrombosis.
Recent trauma was defined as trauma that occurred 14 to 30 days before the
onset of DVT.
Previous orthopedic surgery was defined as surgery experienced 30 to 90 days
before the onset of DVT.
The scope for a classification of immobilization was 4 to 30 days before the
onset of DVT.
Thrombophilia was defined as documented biochemical hypercoagulable
disorders, such as protein C or S deficiency and Factor V Leiden.
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symptoms promptly, maintain venous valve function, and
reduce recurrence of DVT.7,8 Consequently, clinical use of
thrombolytic agents has received significant attention because
of the impressive thrombolysis achieved with CDT. A large
study has demonstrated that CDT can achieve a complete or
partial thrombolysis rate of at least 83% compared to treat-
ment with anticoagulation alone.8e10,20
The present study retrospectively compared enoxaparin
with CDT for efficacy and safety and the evolution of acute
proximal DVT in the lower limbs.
2. Methods
Approval froman institutional reviewboardofTaipeiVeterans
General Hospital was obtained for this retrospective study, which
included a waiver of informed consent. This retrospective study
involved 53 patients who had experienced symptoms of acute
proximal DVT for<14 days. They received either CDT followed
by intravenous UFH or body-weight-adjusted subcutaneous
enoxaparin for 7e14 days. Warfarin was administered to all pa-
tients for at least 6 months between January 2009 and October
2010.The patients comprised 26womenand27men,with amean
age of 62 16.2 years (range: 34e84years). Twenty-seven of the
patients were treatedwith CDT (i.e., the CDT group) followed by
UFH, and26 were treated with LMWH alone (i.e., the control
group). The primary symptoms were limb swelling, discolor-
ation, pain, and venous claudication in the majority of patients.
Duplex sonography was first used to diagnose DVT and then to
confirm the extent of DVT among the patients. The evolution of
DVTwas analyzed according to the thrombus score (TS) classi-
fication modified by Haenen et al and Porter et al.11,12 The mean
duration of the follow-up was 15.2 months.
Patient characteristics and clinical parameters are shown in
Table 1. The relevant medical history, physical examinations,
and diagnostic test results, including those from phlebography
and color duplex ultrasound, were reviewed for all patients.
Patients recruited for this study were required to have acute
proximal DVT of the lower limbs. Exclusion criteria
comprised severe anemia, severe renal failure, active internal
bleeding, thrombocytopenia, bilateral DVT, and contraindi-
cations to thrombolytic treatment such as hemorrhagic stroke
or other intracranial disease, major surgery within 30 days,
intractable hypertension, and prolonged traumatic cardiopul-
monary resuscitation.2.1. Antithrombotic therapy and thrombolytic techniquesAntithrombotic therapy was administered according to the
clinical practice guidelines of the ACCP. We provided patients
with LMWH for 7e14 days followed by oral warfarin for at
least 6 months, while ensuring they presented an international
normalized ratio (INR) of 2e3.1
The CDT protocol of this study was modified from the
CaVenT Study (catheter-directed venous thrombolysis in acute
iliofemoral vein thrombosis trial).8 Informed consent was
obtained from each patient who was willing to undergo CDT.Before performing the CDT procedure, the antithrombotic
medication of patients was temporarily not given to obtain an
INR of <1.5. At the beginning of the CDT procedure, an
intravenous bolus of 3000e5000 U of UFH was administered
to obtain an activated clotting time of >200 s.
Briefly, percutaneous entry was achieved either through the
lesser saphenous vein or the popliteal vein under ultrasound
guidance. After the lesser saphenous vein was punctured, a 5-F
or 6-F introducer sheath was inserted into the thrombosed
vessel over a guide wire. Venography was performed to
determine the extent of the thrombus. The guide wire and
catheter were advanced above the proximal part of the
thrombus. Then, appropriate multiside-hole infusion catheters
were exchanged and secured in place. After the procedure,
CDT was initiated with urokinase. The urokinase solution was
continuously infused at a dose of 600e1200 U/kg/h over
48e72 h. The dosage of urokinase was adjusted according to
the fibrinogen and hemoglobin levels and platelet counts.
During CDT therapy, UFH was simultaneously administered
via the sheath at a low dose of 5e10 U/kg/h. The activated
partial thromboplastin time (aPTT) was maintained at 1.5e2.0
times greater than the control levels.
Patients’ blood pressure, pulse, and the puncture site were
checked four times daily. Hemoglobin and fibrinogen levels
and platelet counts were measured daily. aPTT was examined
twice daily. After the completion of CDT, systemic intrave-
nous UFH was administered continuously to maintain an aPTT
ratio 1.5e2.5 times greater than the control levels. Simulta-
neously, warfarin was administered and overlapped with UFH
treatment for 4e5 days until an INR of 2e3 was achieved on 2
consecutive days.
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ings were provided to all patients. Additionally, ambulation
was initiated as soon as possible.2.2. Safety and efficacy outcome measuresThe study endpoints were DVT evolution and treatment
safety and efficacy outcomes. These endpoints were assessed
via clinical findings, and vascular laboratory instruments at
pre-established times (i.e. baseline, 7 days, 1 month, 3 months,
and 6 months). During the treatment, all patients were
assessed for liver function, renal function, fibrinogen, pro-
thrombin time, aPTT, D-dimer, and blood and platelet counts.
The safety outcome calculated the occurrence of bleeding
and serious adverse events such as pulmonary embolism and
death. Major bleeding was defined as obvious bleeding, such
as intracranial bleeding, gastrointestinal bleeding, and retro-
peritoneal hematomas, which resulted in either hemodynamic
instability, a blood transfusion of >2 U, surgery, or death. All
other bleeding events were considered minor episodes.
The efficacy outcomes included early and immediate ilio-
femoral venous patency, valvular competence, recanalization
of occluded veins, thrombus progression or resolution, recur-
rent DVT, and PTS. The development of DVT and the
assessment of efficacy outcomes were conducted using duplex
ultrasound and either plethysmography or venography at pre-
established times (i.e., baseline, 7 days, 1 month, 3 months, 6
months, and 12 months).
Color Doppler ultrasound was performed by vascular phy-
sicians and experienced technicians. The evolution of DVTwas
analyzed according to the thrombus score (TS) classification
modified by Haenen et al and Porter et al.11,12 The standardized
definitions of the degree of thrombosis, vein segment classifi-
cations (i.e., external iliac, common femoral, proximal and
distal femoral, popliteal, and great saphenous veins), and scores
for the degree of venous obstruction (i.e., 0 ¼ open vein free of
thrombus; 1 ¼ partially occluded vein with a flow Doppler
signal; and 2 ¼ completely occluded vein with no flow signal)
were determined. In each leg, TS before and after thrombolysis
was calculated by summing the TS of the six vein segments
(TStotal). ATStotal increase indicated DVT progression, whereas
decreased TStotal indicated regression (i.e., complete lysis or
incomplete lysis).When TStotal remained the same at follow-up,
no changes in DVTwere considered.
Venous insufficiency was also evaluated with Doppler ul-
trasound, and a valvular reflux >0.5 s was set as valve
incompetence of the involved segment.13
Venous outflow (VO) resistance was assessed using air
plethysmography. A tourniquet (10e12 cm wide) was placed
at the thigh segment and inflated to 80 mmHg. Volume
increased to a new plateau. The tourniquet was then deflated
suddenly, and the VO curve was recorded. The outflow frac-
tion at 1 s (OF1) was the VO expressed as a percentage of the
total venous volume. An OF1 >38% was considered clinically
to indicate the absence of any functional obstruction; 30e38%
indicated moderate obstruction; and <28% indicated severe
obstruction.14After 12 months, PTS was assessed using the Villalta
scale,15 which included five symptoms (pain, cramps, heavi-
ness, pruritus, and paresthesia) and six indications (edema,
skin induration, hyperpigmentation, venous ectasia, redness,
and pain during calf compression). Each indication or symp-
tom was rated as either 0 (absent), 1 (mild), 2 (moderate), or 3
(severe). Points were then summed to determine the total
score. A total score >15 or a venous ulcer indicated severe
PTS, and a total score of 5e14 was considered mild to mod-
erate PTS.
The venous registry index was used to classify DVT pa-
tients receiving CDT treatment. The degree of thrombolysis
was determined from the differences between the pre- and
post-thrombolysis thrombus of each involved segment using
various interval venography. Complete thrombolysis (grade
III) was when clot lysis of 95e100% was achieved, partial
thrombolysis (grade II) was when clot lysis of 50e90% was
achieved, and minimal or no thrombolysis (grade I) was when
clot lysis of <50% was achieved.162.3. Statistical analysisContinuous variables were reported as means  standard
deviations. Baseline demographic and clinical characteristics
between the CDT and anticoagulant groups were compared
using a two-sided ManneWhitney test. Differences between
the anticoagulant and CDT groups were determined using
Fisher’s exact test for dichotomous variables. A p value <0.05
was considered statistically significant. All statistical analyses
were performed using SPSS software.
3. Results
From January 2009 to October 2010, we recruited 53 pa-
tients with acute proximal DVT of less than 14 days, who
received either CDT followed by intravenous UFH or only
body-weight-adjusted subcutaneous enoxaparin. The baseline
demographics and clinical characteristics of these patients
were compared and are shown in Table 1. No significant dif-
ferences existed between the two treatment groups Table 2.3.1. DVT evolutionDuring the follow-up period, changes over time in the
number of thrombosed vein segments were assessed with
duplex ultrasound for all 53 patients, at pre-established times
(i.e., baseline, and after 7 days, 1 month, 3 months, and 6
months). Therefore, according to the mean TStotal score, the
cumulative incidence of recanalization of thrombosed vein
segments increased steadily in both groups, but was more
prominent in the CDT group (Fig. 3). Recanalization was
found in 89% of the CDT group at 3 months and 93.2% at 6
months, whereas 37.4% of the control group experienced
recanalization at 3 months and 54% at 6 months. Furthermore,
early recanalization was more prominent in the CDT group
after 1 week to 3 months of treatment ( p < 0.001) (Fig. 3).
Table 2
Inclusion and exclusion criteria.
Inclusion criteria
Age 25e85 years
Onset of symptoms <14 days
First time verified deep vein
Thrombosis limited to the upper thigh, iliofemoral segment
Before the start of CDT, informed consent obtained.
Exclusion criteria
Anticoagulant therapy before trial entry
Contraindication to thrombolytic treatment, including
Bleeding diathesis
Hemorrhagic stroke
Major surgery &1 month
Severe hypertension with persistent systolic blood pressure S180 mmHG
or diastolic blood pressure S100 mmHg
Severe renal failure e estimated creatinine clearance <25 ml min1
Severe anemia (hemoglobin <8 gdL1
Thrombocytopenia (platelets <100  109 L1
Primary or metastatic central nervous system malignancy
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formed to evaluate the degree of thrombolysis after CDT
treatment. Complete lysis was found in 12 patients, and partial
lysis (grade II) was found in 15 patients following the
completion of CDT treatment. These results were comparable
to the ultrasonographic findings. Furthermore, three of the 12
patients with complete lysis received percutaneous angioplasty
and Wallstents for stenotic lesions in the left common iliac
veins (Fig. 2).3.2. Efficacy outcomes at 1 week, 1 month, 3 months,
and 6 monthsIn the control group, four patients experienced thrombus
progression; thus, LMWH therapy was prolonged by >10 days
for these cases. During the follow-up period, three cases of
recurrent DVT occurred; specifically, one case occurred in the
CDT group, and the other two in the control group (Table 3).
Of these three patients with recurrent DVT, two experienced
malignancies, and one experienced anal bleeding.
In the CDT group, patency of the iliofemoral vein segment
was observed in 42.3% of the patients after 1 week and 69.2%Fig. 1. Cumulative incidence of complete lysis (iliofemoral patency) in both
the CDT and LMWH groups.after 6 months. However, in the control group, patency was
observed in only 15.4% of the patients after 3 months and
38.5% after 6 months. Significant differences existed between
the CDT and the control groups for the patency of the iliofe-
moral vein segment (Fig. 1 and Tables 3 and 4).
Femoral venous obstruction was found in only 30.8% of
CDT patients compared to 61.5% of the control group after
6months ( p ¼ 0.05). Femoral venous insufficiency was
observed in 46.2% of the CDT group and 53.9% of the control
group; no significant differences were found after 6 months
( p ¼ 0.782) (Table 4).
The degree of PTS after 12 months is shown in Table 3.
After 12 months, PTS was found in 19.2% of the CDT group
compared to 50% of the control group; significant differences
were also observed ( p ¼ 0.04) (Table 4).3.3. Safety outcomesDuring therapy, two patients in the CDTgroup did not receive
complete thrombolytic treatment because they experienced
bleeding complications. Of these two patients, one (female) re-
ported episodes of oral bleeding related to tonsil abscess rupture,
and consequently required a blood transfusion of 2 U packed red
blood cells. The other patient (male) suffered anal bleeding, and
subsequently required surgical treatment for hemorrhoids.
Therefore, these two patients showed ineffective thrombolysis.
However, no significant differences were observed between the
two groups for bleeding events during this study (Table 5).
4. Discussion
After initial treatment, patients’ symptoms of acute DVT,
such as leg swelling, tightness, and pain, typically disappeared
rapidly. In our ultrasonographic observations, the following
factors were primarily responsible for the immediate resolu-
tion of these symptoms: (1) recovery of VO (i.e., recanaliza-
tion) and (2) the development of bypassing collateral veins. As
observed by Thomas et al,17 the resolution of these symptoms
is primarily the result of bypassing collateral veins, which are
typically detected around the occluded vein segment imme-
diately following LMWH treatment. In the present study, pa-
tients undergoing CDT experienced rapid resolution of their
symptoms, which primarily resulted from effective throm-
bolysis and early vein recanalization (Figs. 1 and 3).
A review of the relevant literature suggests that CDT and
LMWH substantially influence thrombus regression and pre-
vent recurrent DVT.8,12,19e21,23 In the present study, recana-
lization occurred in 74.7% and 89% of the CDT group after 1
week and 3 months of treatment, respectively. However, only
37.4% and 54% of the control group experienced recanaliza-
tion at 3 and 6 months, respectively. Furthermore, CDT has
been shown to be effective in achieving short- and
intermediate-term venous patency.8e10,18e20 These series on
CDT reported a 6-month patency of 60e85% compared to
69.2% in the present study. Thus, CDT appears to achieve
early recanalization and superior venous patency in an acute
setting compared to anticoagulants alone. However, the
Fig. 2. (A) Contrast venography showing stenosis of the left common iliac vein; (B) observation of Wallstent placement and continued antegrade flow.
Table 3
Noninvasive assessments of vein patency after 1 week and 1, 3, and 6 months
after treatment.
Endpoints Anticoagulation group
(n ¼ 26) n (%)
CDT group
(n ¼ 26) n (%)
p
Complete lysis (Iliofemoral patency)
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functional venous outcomes have yet to be clarified. This
was also one of the study limitations.
Numerous studies have shown that CDT and LMWH have
significant effects on the regression of thrombus and the pre-
vention of recurrent DVT and subsequent PTS.9,10,18,19,21,22,24
These series have reported a thrombus regression rate of
w58.3% for enoxaparin and <50% for UFH after 6 months. In
the present study, the regression rate was 54% for enoxaparin
and 93.2% for CDT treatment after 6 months (Figs. 1 and 3).
Specifically, after 12 months, the CDT group had a signifi-
cantly higher number of patients with a comparatively favor-
able degree of PTS ( p ¼ 0.04) (Table 4). This indicates that
CDT may reduce PTS development because of its superior
thrombus resolution and early recanalization.
From a clinical practice and follow-up perspective, venog-
raphy is a relatively invasive and inconvenient procedure.
Therefore, during treatment follow-up, all patients underwent
duplex ultrasound, which is a valid alternative to venography for
predicting the presence of thrombosis in patients with acute
proximal DVT.23 A few studies have discussed the clinical and
ultrasonographic differences between CDT and LMWH treat-
ment among patients with proximal DVT of the lower limbs.Fig. 3. Recanalization of the thrombosed veins of patients in both the CDT and
the LMWH groups developed according to the mean total thrombus score.Thus, a head-to-head analysis comparing CDT and LMWH
should provide substantial information of DVTevolution and of
the treatment efficacy and safety.
In the present study, CDT was successfully performed in
most patients (n ¼ 25). The incidence of major bleeding
events was similar to that reported by other studies.8,20 Only
two patients experienced major bleeding events that required
blood transfusions, and both recovered rapidly without
sequelae. Thus, CDT treatment appears to be as safe as anti-
coagulation (Table 5). Additionally, three patients in the CDT
group received angioplasty and Wallstents for stenotic lesions
in the common iliac veins. The number of patients in this
group was limited, therefore, no significant differences were
observed between the two study groups. Nevertheless, in
addition to the treatment for proximal DVT, the use of ancil-
lary treatments, specifically angioplasty and stents, should be1 week 0 11 (42.3%) <0.001
1 month 0 14 (53.8%) <0.001
3 months 4 (15.4%) 17 (65.4%) 0.001
6 months 10 (38.5%) 18 (69.2%) 0.05
Incomplete lysis (Recanalization)
1 week 1 (3.8 %) 15 (57.7%) <0.001
1 month 16 (61.5%) 12 (46.2%) 0.404
3 months 15 (57.7%) 8 (30.8%) 0.093
6 months 14 (53.8%) 8 (30.8%) 0.160
No lysis (no flow and/or incompressibility)
1 week 23 (88.5 %) 0 <0.001
1 month 8 (30.8%) 0 0.004
3 months 5 (19.2%) 0 0.051
6 months 2 (7.7 %) 0 0.490
Progression 4 (15.4%) 0 0.110
1 week 2 (7.7 %) 0
1 month 2 (7.7 %) 0
Recurrent DVT 2 (7.7 %) 1 (3.8%) 1.000
1e3 months 2 1
Table 4
Venous outcomes at 6 months and PTS at 12 months after treatment.
Outcomes Anticoaglution
group
CDT group p
No obstruction (Iliofemoral
patency)
10 (38.5%) 18 (69.23%) 0.05
Functional venous obstruction 16 (61.5%) 8 (30.8%) 0.05
Severe (No lysis) 5 (7.7%) 3 (11.5%) 0.703
Moderate (partial lysis) 11 (42.3%) 5 (19.2%) 0.132
Femoral venous insufficiency 14 (53.9%) 12 (46.2%) 0.782
1 s > RD S0.5 s 6 8 0.755
RD S1 s 8 4 0.324
Postthrombotic syndrome 13 (50%) 5 (19.2%) 0.04
Mild to moderate PTS 10 (46.2%) 5 (19.2%) 0.22
Severe PTS 3 (11.5%) 0 0.235
RD ¼ Reflux duration; PTS ¼ Postthrombotic syndrome.
Table 5
Bleeding and serious adverse events that occurred during the study period.
Events Anticoaglution group CDT group p
Major bleeding 0 2 0.491
Oral bleeding 0 1
Anal bleeding 0 1
Minor bleeding 5 6 1.000
Gross hematuria 0 0
Microscopic hematuria 2 3
Skin ecchymosis 3 0
Puncture site hematoma 0 3
Pulmonary embolism 0 0
Total events 5 8 0.526
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venous patency. Large prospective randomized studies that
focus on the short- and long-term outcomes of adjuvant an-
gioplasty and stents in patients have yet to be conducted.
In conclusion, our short-term results suggest that CDT
treatment is as safe as anticoagulation and provides greater
thrombus resolution and earlier recanalization, which may
preserve venous function and further prevent PTS. In addition,
duplex ultrasound analysis of thrombus progression is useful for
assessing the treatment of patients with acute proximal DVT.
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